The analysis showed that CKI combined with chemo significantly improved clinical efficiency compared with chemo alone in patients with NSCLC (RR = 1.21, 95% CI: 1.06 to 1.37; P=0.003) (Figure 2). The gene discussed is CHKA; the disease is non-small cell lung carcinoma.